



DIGITAL ACCESS TO
SCHOLARSHIP AT HARVARD
DASH.HARVARD.EDU

HARVARD
LIBRARY



Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

Citation

Published version

<https://doi.org/10.1038/bjc.2015.377>

Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:29739136>

Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#)

Keywords: epithelial ovarian cancer; menopausal hormone therapy; survival; oral contraceptives; parity

Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study

Jelena Bešević¹, Marc J Gunter¹, Renée T Fortner², Konstantinos K Tsilidis^{1,3}, Elisabete Weiderpass^{4,5,6,7}, N Charlotte Onland-Moret⁸, Laure Dossus^{9,10,11}, Anne Tjønneland¹², Louise Hansen¹², Kim Overvad¹³, Sylvie Mesrine^{9,10,11}, Laura Baglietto^{14,15}, Françoise Clavel-Chapelon^{9,10,11}, Rudolf Kaaks², Krasimira Aleksandrova¹⁶, Heiner Boeing¹⁶, Antonia Trichopoulou^{17,18}, Pagona Lagiou^{19,20}, Christina Bamia²⁰, Giovanna Masala²¹, Claudia Agnoli²², Rosario Tumino²³, Fulvio Ricceri^{24,25}, Salvatore Panico²⁶, HB(as) Bueno-de-Mesquita^{1,27,28,29}, Petra H Peeters^{1,8}, Mie Jareid⁴, J Ramón Quirós³⁰, Eric J Duell³¹, María-José Sánchez^{32,33}, Nerea Larrañaga^{33,34}, María-Dolores Chirlaque^{33,35}, Aurelio Barricarte^{33,36,37}, Joana A Dias³⁸, Emily Sonestedt³⁸, Annika Idahl^{39,40}, Eva Lundin⁴¹, Nicholas J Wareham⁴², Kay-Tee Khaw⁴³, Ruth C Travis⁴⁴, Sabina Rinaldi⁴⁵, Isabelle Romieu⁴⁵, Elio Riboli¹ and Melissa A Merritt^{*,1,46}

Background: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521 330 total participants (approximately 370 000 women) aged 25–70 years at recruitment from 1992 to 2000.

Methods: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.

Results: After a mean follow-up of 3.6 years (± 3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62–1.03) and a significant survival benefit in long-term MHT users (≥ 5 years use vs never use, HR=0.70, 95% CI=0.50–0.99, $P_{trend}=0.04$). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.

Conclusions: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

Ovarian cancer is the seventh most common cause of cancer mortality among women worldwide and the most lethal gynaecological malignancy (Allemani *et al*, 2014). It is well established that epithelial ovarian cancer (EOC) has a hormonal aetiology as evidenced by the lower risk of developing EOC among women who are parous (Riman *et al*, 2004; Whittemore *et al*, 1992) or oral contraceptive (OC) users (Beral *et al*, 2008; Tsilidis *et al*, 2011;

Fortner *et al*, 2015) and the higher EOC risk with use of menopausal hormone therapy (MHT) (Beral *et al*, 2015). The changes in steroid hormone signalling that underlie these risk associations are complex and little understood; however, in general it is thought that higher oestrogen levels may promote ovarian carcinogenesis (Cramer and Welch, 1983; Cuna *et al*, 2004), while higher levels of progestins and progesterone may have a protective

*Correspondence: Dr MA Merritt; E-mail: m.merritt@imperial.ac.uk

⁴⁶Current address: Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK.

Received 29 July 2015; revised 6 October 2015; accepted 8 October 2015; published online 10 November 2015

© 2015 Cancer Research UK. All rights reserved 0007–0920/15

role against EOC (Risch, 1998; Modugno *et al*, 2012). Given the association between reproductive factors and EOC incidence, and its hypothesised hormonal aetiology, it is plausible that reproductive factors may also influence EOC prognosis.

Patient age and tumour characteristics, such as stage and histological subtype, are important prognostic factors. For example, cases diagnosed with the most common (serous) histological subtype of EOC have a poor prognosis as compared with other subtypes (endometrioid, mucinous and clear cell) (Rosen *et al*, 2009). Epidemiological studies may provide further insights about the possible links between reproductive factors and EOC survival while accounting for known clinical prognostic factors. In a large Australian case-control study including 676 EOC cases (419 deaths) (Nagle *et al*, 2008), women who had ever *vs* never breastfed had an improved survival, but there was no trend with breastfeeding duration. In contrast, other studies (Jacobsen *et al*, 1993; Kjaerbye-Thygesen *et al*, 2006; Robbins *et al*, 2009; Zhang and Holman, 2012) reported no association with breastfeeding. In a prospective study of 644 EOC cases (419 deaths) from a Norwegian breast screening cohort (Jacobsen *et al*, 1993), an older age at first birth was associated with worse survival but there was no apparent trend, and this result was not confirmed by other studies (Kjaerbye-Thygesen *et al*, 2006; Nagle *et al*, 2008; Yang *et al*, 2008). Three previous studies (each with ≥ 649 EOC cases identified from population-based case-control studies) investigated MHT use and observed no influence on survival among all EOC cases (Mascarenhas *et al*, 2006; Nagle *et al*, 2008; Wernli *et al*, 2008); however, in the two studies that evaluated serous cases, one reported improved survival in ever *vs* never users of MHT (HR = 0.69, 95% CI 0.48–0.98) (Mascarenhas *et al*, 2006), while there was no association in the other study (Nagle *et al*, 2008). Because of the inconsistent findings reported across studies, further research is needed to assess the possible influence of reproductive factors on EOC survival. In the current study, we investigated prediagnostic reproductive characteristics in relation to EOC-specific survival among EOC cases overall and serous cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

MATERIAL AND METHODS

Study population. The study design has been previously detailed (Riboli *et al*, 2002). In brief, the EPIC cohort includes > 500 000 individuals, of which approximately 370 000 are women. The participants were mainly recruited from the general population who resided in 23 study centres in 10 European countries, Denmark, France, Spain, Germany, The Netherlands, Greece, Italy, Norway, Sweden and the United Kingdom, between 1992 and 2000. Exceptions to this included: French participants were recruited through health insurance databases; some members of the Italian and Spanish cohorts were recruited via local blood donor registries; some members of the Utrecht and Florence cohorts were recruited through local breast screening programmes; and approximately half of the Oxford cohort included individuals who did not eat meat. Ethics approval for the study was obtained from the International Agency for Research on Cancer and the local review boards at the participating centres.

Outcome assessment. According to the improved understanding of ovarian cancer pathogenesis (Jarboe *et al*, 2008; Kurman and Shih, 2011), we defined incident 'ovarian' cancer cases using the International Classification of Disease for Oncology (ICD-O-3) codes C56.9, C57.0 and C48, including primary peritoneal and fallopian tube cancers. Cases were identified through linkage with national cancer registries in Denmark, Italy, The Netherlands, Norway, Spain, Sweden and the UK. In France, Germany and

Greece, cases were identified using insurance records, cancer registries and active follow-up of participants. Data on tumour invasiveness, histology, stage and grade were available from cancer registries and a pathology record review. Information on vital status, the causes and dates of death were obtained using record linkages with cancer registries, boards of health and death indices in Denmark, Italy (except Naples), The Netherlands, Norway, Spain, Sweden and the UK or through active follow-up (inquiries by mail or telephone to participants, municipal registries, regional health departments, physicians and hospitals) in Germany, Greece, Naples (Italy) and France. Causes of death were reported as specified by the International Statistical Classification of Diseases, Tenth revision (ICD-10). As different procedures were used to obtain follow-up data on vital status across the study centres, this resulted in differences across the centres in the timing to report the causes of death. To account for this, the follow-up dates were truncated to when 80% of the causes of death at each centre were known (June 2005–June 2009) with the following exceptions; in Greece and Germany, the date of last known contact was the date of censoring and this extended to November 2009 for Greece and February 2010 for Germany. Data were unavailable to examine recurrent EOC in the current study.

We identified 1405 ovarian cancer cases and the following exclusions were used: not first incident ($n = 60$); non-epithelial cancer or unknown histology ($n = 95$); missing date of death ($n = 4$); unknown vital status ($n = 2$); ovarian cancer diagnosed after the vital status censoring date ($n = 84$); date of diagnosis was the same as date of death ($n = 6$); missing extensive information on reproductive history, specifically age at menarche, number and age at first full term pregnancy (FTP), OC use and breastfeeding duration ($n = 28$); borderline EOC cases ($n = 99$); tumours missing invasiveness ($n = 2$); leaving 1025 invasive EOCs in the current analysis. The outcome of interest was death from EOC or an EOC-related cause, defined as death owing to possible metastatic tumours, including peritoneum not otherwise specified (NOS), specified parts of the peritoneum, fallopian tube, corpus uteri and uterus NOS. Of the $n = 554$ total deaths that were observed, an EOC-specific death was recorded for $n = 511$ (92%) and deaths that occurred owing to other causes ($n = 43$) were censored.

Exposure assessment. At the time of study recruitment, participants completed questionnaires on reproductive history, diet and lifestyle. Data collection procedures were centralised as a single study with multiple centres. Reproductive variables that were investigated included parity (live births and still births only; number and age at first FTP), ever breastfed and duration, OC use and duration, age at menarche and menopause, hysterectomy and total ovulatory lifespan. For the MHT variables (assessed at recruitment), participants were asked if they had ever used MHT, the timing of use (whether they were current users), their age at start and total duration of use. The duration of MHT use refers to the total duration for the former users or the duration up until the time of recruitment among the current users. Information on MHT formulation was only available from women who reported that they were currently using MHT at recruitment. Information on the time since last MHT use was unavailable. Menopausal status was defined using information on menstruation status, hysterectomy, oophorectomy, use of exogenous hormones and age as detailed previously (Lahmann *et al*, 2004). Breastfeeding duration was only available for the first three and the last FTP, therefore for women reporting > 4 FTPs the duration was estimated as the number of pregnancies multiplied by the mean duration of breastfeeding per child. The total ovulatory lifespan was calculated as the difference between a participant's age at menopause and their age at menarche (postmenopausal) or the difference between their age at recruitment and age at menarche (premenopausal, perimenopausal), less the time that she was pregnant, calculated as the number of FTPs multiplied by

0.75 (equivalent to 9 months), and/or used OCs. Data on tubal ligation, family history of ovarian cancer and BRCA1/2 status were not available for any of the cases. Age at last FTP was not assessed because this information was unknown for 88% of the parous cases and family history of breast cancer was not examined as a confounder because this information was missing for 56% of the cases.

Statistical analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models. Person-time was calculated as the number of days between EOC diagnosis and the date of death, emigration, loss to follow-up or censoring, whichever occurred first. Multivariable models were adjusted for covariates that were selected *a priori* because of their known influence on risk of EOC death; age at diagnosis (continuous), BMI ($<23 \text{ kg m}^{-2}$, ≥ 23 – <25 (reference), ≥ 25 – <30 , ≥ 30), tumour stage (local (reference), regional, metastatic, unknown) and smoking status (never (reference), former, current, unknown). We further adjusted for the year of diagnosis (continuous) to account for possible changes in the treatment regime for ovarian cancer over time. All models were stratified by study centre. We tested whether additional adjustment for the following potential confounders (education level, marital status, physical activity and alcohol intake) or tumour characteristics (histologic subtype and grade) changed the risk estimates by $\geq 10\%$ (Greenland, 1989), but the risk estimates were very similar therefore none of these factors were included in the final models. Other than education level, additional measures of social class were not available in this study. The P_{trend} was calculated by entering continuous terms into the regression model. Analyses were conducted using the survival package (Therneau, 2014) in R version 3.0.2 (R Core Team, 2014). The proportional hazards assumption was tested using the method described by Grambsch and Therneau, 1994.

We carried out the following stratified analyses by: age at diagnosis (<65 years, ≥ 65 years), because older women may be less likely to be offered standard treatments and more likely to develop toxicity (Tew *et al*, 2014); BMI ($<25 \text{ kg m}^{-2}$, $\geq 25 \text{ kg m}^{-2}$) because obese women may have a decreased survival owing to surgical complications and/or inadequate chemotherapy dosing (Modesitt and van Nagell, 2005); histological subtype (serous, non-serous, including endometrioid, mucinous and clear cell); and tumour stage (early-stage/FIGO SI/II, late-stage/FIGO SIII (Prat, 2014)). Interaction terms (P_{int}) between the binary stratifying variables and the categorical reproductive variables were included in multivariable models and were compared with models without interaction terms using the likelihood ratio test. Sensitivity analyses were carried out after restricting analyses to a uniform subgroup of cases that were classified as the most common (serous) histological subtype, cases who were diagnosed with SII/III tumours, cases with tumours from the ovary (C56.9) only and participants who were postmenopausal at recruitment. We also examined MHT use variables after additionally adjusting for hysterectomy status. Statistical significance was set at $P < 0.05$.

RESULTS

The study population included 1025 women diagnosed with EOC. The median (range) of the participant ages was 54 years (26, 86) and 61 years (34, 98) at the baseline questionnaire completion and at cancer diagnosis, respectively. During a mean follow-up of 3.6 years (± 3.2 s.d.), 511 individuals (49.9%) died from ovarian cancer. Survival analysis of clinical and demographic characteristics showed that older age, poorly/undifferentiated tumour grade, advanced stage and current smoking at the study baseline were associated with a worse EOC-specific survival (Table 1). Compared with serous cases, women with endometrioid tumours

had a better prognosis (HR = 0.53, 95% CI = 0.37–0.75), whereas cases with NOS tumours had a poorer prognosis (HR = 1.41, 95% CI 1.11–1.79).

We investigated reproductive factors that were assessed on average 5.9 years (± 3.4 s.d.) prior to the diagnosis of EOC. In the

Table 1. Association between clinicopathological and demographic factors in relation to survival among EOC cases

	Total ^a n	Fatal cases ^b n(%)	HR ^c	95% CI
Age at diagnosis^d, years				
<50	103	44 (42.7)	Ref.	
50–59	361	160 (44.3)	1.25	0.88–1.79
60–69	411	218 (53.0)	1.68	1.17–2.41
70+	150	89 (59.3)	2.58	1.71–3.90
P_{trend}				<0.001
Tumour site				
Ovary	960	482 (50.2)	Ref.	
Other ^e	65	29 (44.6)	1.01	0.67–1.53
Histology				
Serous	568	298 (52.5)	Ref.	
Mucinous	74	27 (36.5)	1.16	0.77–1.77
Endometrioid	126	39 (31.0)	0.53	0.37–0.75
Clear cell	49	13 (26.5)	0.82	0.46–1.46
NOS	164	111(67.7)	1.41	1.11–1.79
Other ^f	44	23 (52.3)	1.20	0.77–1.90
Grade^g				
Well differentiated	64	13 (20.3)	Ref.	
Moderately differentiated	210	95 (45.2)	1.99	1.07–3.70
Poorly/undifferentiated	345	193 (55.9)	2.41	1.31–4.43
FIGO stage^h				
Stage I	141	21 (14.9)	Ref.	
Stage II	78	27 (34.6)	2.77	1.54–4.98
Stage III	300	176 (58.7)	6.34	3.96–10.17
Stage IV	101	61 (60.4)	10.54	6.16–18.03
Stageⁱ				
Local	138	18 (13.0)	Ref.	
Regional	171	62 (36.3)	3.31	1.94–5.64
Metastatic	586	360 (61.4)	8.64	5.32–14.04
Body mass index, kg m^{-2}				
<23	318	149 (46.9)	0.99	0.76–1.28
23–24.9	235	114 (48.5)	Ref.	
25–29.9	316	169 (53.5)	1.01	(0.79–1.30)
30+	156	79 (50.6)	0.85	(0.62–1.16)
Smoking status^j				
Never smoker	567	285 (50.3)	Ref.	
Former smoker	235	113 (48.1)	1.09	(0.86–1.37)
Current smoker	204	104 (51.0)	1.56	(1.22–1.99)

Abbreviations: CI = confidence interval; EOC = epithelial ovarian cancer; FIGO = International Federation of Gynecology and Obstetrics; HR = hazard ratio; NOS = not otherwise specified.

^aTotal number of cases $n = 1025$.

^bTotal number of fatal cases $n = 511$.

^cAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI ($<23 \text{ kg m}^{-2}$, ≥ 23 – <25 (reference), ≥ 25 – <30 , ≥ 30), tumour stage (local (reference), regional, metastatic and unknown), smoking status (never (reference), former, current and unknown) and stratified by study centre.

^dAdjusted for all factors mentioned above in footnote c except for age at diagnosis as this was the variable of interest.

^eIncludes fallopian tube and primary peritoneal carcinomas.

^fThe 'other' histological subtype category included 'Neoplasm, malignant' (31.8%), 'Carcinoma, undifferentiated, NOS' (25.0%) and 'Carcinosarcoma, NOS' (11.4%) and a small number of 'Carcinoma, anaplastic, NOS', 'Pseudosarcomatous carcinoma, NOS', 'Transitional cell carcinoma, NOS', 'Solid carcinoma, NOS', 'Mullerian mixed tumour', 'Mesodermal mixed tumour' and 'Brenner tumour, malignant'.

^gGrade was missing for 39.6% of the cohort.

^hFIGO stage was missing for 39.5% of the cohort.

ⁱStage is closely related to FIGO stage but is more complete across the cohort (12.7% missing).

^jSmoking status was missing for 1.9% of the cohort.

Table 2. Association between prediagnostic reproductive factors and survival among EOC cases overall

	Total ^a n	Fatal cases ^b n (%)	Model 1 HR ^c	95% CI	Model 2 HR ^d	95% CI
Age at menarche^e, years						
< 12	158	83 (52.5)	Ref.		Ref.	
12	187	86 (46.0)	0.89	0.65–1.22	1.01	0.74–1.38
13	253	125 (49.4)	0.91	0.68–1.22	0.84	0.63–1.13
14	223	107 (48.0)	0.84	0.62–1.13	0.75	0.55–1.01
> 14	186	100 (53.8)	0.93	0.68–1.27	0.90	0.66–1.24
<i>P</i> _{trend}				0.76		0.37
Parous^e						
No	169	86 (50.9)	Ref.		Ref.	
Yes	833	414 (49.7)	0.97	0.77–1.24	0.90	0.71–1.14
Number of FTPs^{e,f}						
1	159	75 (47.2)	Ref.		Ref.	
2	394	190 (48.2)	1.07	0.81–1.41	1.04	0.78–1.38
3+	262	142 (54.2)	1.17	0.88–1.57	1.10	0.81–1.49
<i>P</i> _{trend}				0.13		0.31
Age at first FTP^{e,f}, years						
≤20	118	66 (55.9)	Ref.		Ref.	
> 20–≤25	376	167 (44.4)	0.65	0.48–0.87	0.66	0.49–0.90
> 25–≤30	244	125 (51.2)	0.72	0.53–0.99	0.72	0.52–1.00
> 30	88	52 (59.1)	0.87	0.59–1.26	0.86	0.58–1.28
<i>P</i> _{trend}				0.70		0.59
Breastfeeding^{f,g}						
Never	120	59 (49.2)	Ref.		Ref.	
Ever	660	327 (49.5)	0.82	0.61–1.11	0.83	0.61–1.12
Duration of breastfeeding^{e,h}, months						
≤3	205	104 (50.7)	Ref.		Ref.	
> 3–≤6	122	58 (47.5)	0.88	0.62–1.23	1.02	0.71–1.45
> 6–≤12	156	75 (48.1)	0.76	0.55–1.04	0.88	0.63–1.22
> 12–≤24	127	61 (48.0)	0.84	0.60–1.19	0.97	0.68–1.39
> 24	47	28 (59.6)	1.10	0.69–1.73	1.11	0.69–1.79
<i>P</i> _{trend}				0.90		0.87
OC use^e						
Never	523	273 (52.2)	Ref.		Ref.	
Ever	495	232 (46.9)	1.04	0.86–1.26	0.96	0.79–1.17
Duration of OC use^{i,j}, years						
≤1	112	45 (40.2)	Ref.		Ref.	
> 1–≤5	164	71 (43.3)	0.88	0.59–1.32	0.98	0.65–1.48
> 5–≤10	101	47 (46.5)	1.12	0.72–1.74	1.26	0.80–1.98
> 10	77	49 (63.6)	1.69	1.08–2.64	1.74	1.10–2.75
<i>P</i> _{trend}				0.006		0.01
Age at menopause^{k,l}, years						
≤45	89	52 (58.4)	0.94	0.66–1.33	1.06	0.74–1.53
> 45–≤50	207	121(58.5)	Ref.		Ref.	
> 50–≤52	94	50 (53.2)	0.90	0.64–1.27	0.98	0.69–1.40
> 52	136	77 (56.6)	0.90	0.66–1.22	1.04	0.76–1.41
<i>P</i> _{trend}				0.91		0.71
MHT use^{e,k,m}						
Never	299	176 (58.9)	Ref.		Ref.	
Ever	233	130 (55.8)	0.85	0.66–1.09	0.80	0.62–1.03
MHT timing of use at baseline^{e,k,m}						
Former	69	41 (59.4)	0.94	0.66–1.33	0.85	0.59–1.22
Current	160	88 (55.0)	0.84	0.63–1.12	0.79	0.59–1.06
MHT duration of use at baseline^{k,m,n}, years						
< 5	121	68 (56.2)	0.99	0.73–1.34	0.95	0.69–1.29
≥ 5	86	49 (57.0)	0.76	0.54–1.07	0.70	0.50–0.99
<i>P</i> _{trend}				0.11		0.04
MHT formulation at baseline (current users only)^{k,m,o}						
E only	37	24 (64.9)	0.84	0.54–1.31	0.86	0.54–1.35
E + P	100	52 (52.0)	0.89	0.62–1.27	0.80	0.55–1.16
Other	12	8 (66.7)	1.08	0.50–2.33	0.92	0.42–2.01
Hysterectomy^p						
No	831	411 (49.5)	Ref.		Ref.	
Yes	88	45 (51.1)	0.75	0.54–1.04	0.79	0.57–1.10

Table 2. (Continued)

	Total ^a n	Fatal cases ^b n (%)	Model 1 HR ^c	95% CI	Model 2 HR ^d	95% CI
Total ovulatory years^e						
≤27.5	212	105 (49.5)	Ref.		Ref.	
>27.5–≤33.0	207	99 (47.8)	0.87	0.65–1.17	0.91	0.67–1.23
>33.0–≤36.5	212	94 (44.3)	0.72	0.53–0.96	0.72	0.53–0.97
>36.5	194	106 (54.6)	0.87	0.65–1.17	0.97	0.71–1.31
<i>P</i> _{trend}				0.04		0.12

Abbreviations: CI = confidence interval; EOC = epithelial ovarian cancer; FTP = full term pregnancy; HR = hazard ratio; MHT = menopausal hormone therapy; OC = oral contraceptive.

^aTotal number of cases *n* = 1025.

^bTotal number of fatal cases *n* = 511.

^cAdjusted for age at diagnosis (continuous) and stratified by study centre.

^dAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI (<23 kg m⁻², ≥23–<25 (reference), ≥25–<30, ≥30), tumour stage (local (reference), regional, metastatic and unknown), smoking status (never (reference), former, current and unknown) and stratified by study centre.

^eMissing for <5% of the cohort.

^fAmong parous women only.

^gBreastfeeding was missing for 6.4% of the cohort.

^hAmong parous women who had ever breastfed.

ⁱAmong OC users only.

^jDuration of OC use was missing for 8.3% of women.

^kAmong postmenopausal women only.

^lAge at menopause was missing for 18.6% of postmenopausal women.

^mParticipants from Greece and Sweden were excluded from this analysis as detailed data on MHT use were unavailable.

ⁿMHT duration was missing for 11.2% of individuals who ever used MHT.

^oMHT formulation was missing for 6.9% of individuals who reported current use.

^pHysterectomy was missing for 10.3% of the cohort.

^qTotal ovulatory years was missing for 19.5% of the cohort.

analyses of EOC overall, ever vs never OC use was not associated with EOC-specific survival (HR = 0.96, 95% CI = 0.79–1.17) but among OC users a longer duration of use was associated with a worse survival (>10 years vs ≤1 year of use: HR = 1.74, 95% CI = 1.10–2.75, *P*_{trend} = 0.01; Table 2). Compared with never users of MHT, long-term users (≥5 years vs never users; HR = 0.70, 95% CI = 0.50–0.99, *P*_{trend} = 0.04) had a better prognosis, and there was a non-significant improved survival among ever users (HR = 0.80, 95% CI = 0.62–1.03). There was no apparent influence on survival according to the timing of MHT use (former or current use at the study baseline) or when MHT formulation was evaluated among current users at baseline. In the sensitivity analyses of MHT variables when including additional adjustment for hysterectomy status, we observed similar results to those reported above (data not shown). In the analyses of age at first FTP, we observed a better survival among women who had their first FTP at age >20–≤25 years as compared with age ≤20 (HR = 0.66, 95% CI = 0.49–0.90), but there was no association with the other age at first FTP categories and no apparent trend (*P*_{trend} = 0.59). Finally, there was no association between other reproductive characteristics (parity, number of FTPs, ever breastfed or duration, age at menarche or menopause, hysterectomy or total ovulatory years) and EOC-specific survival. There were no apparent differences in any of the risk associations when stratifying by age at diagnosis or BMI (*P*_{int} ≥ 0.07) (data not shown). When restricting analyses to cases diagnosed with an ovarian primary tumour (not primary peritoneal or fallopian tube site), we observed similar results to those reported above (data not shown).

In the analyses restricted to serous cases, there was little influence of OC use or duration, or other reproductive factors such as parity or breastfeeding, on EOC-specific survival (Table 3). Similar to analyses of EOC overall, we observed better survival among serous cases who reported an age at first FTP of >20–≤25 years vs age ≤20 (HR = 0.59, 95% CI = 0.38–0.92), but none of the other age categories were associated with risk, and there was no evidence of a trend (*P*_{trend} = 0.75). Compared with serous cases who never used MHT, we observed better survival among ever users of MHT (HR = 0.63, 95% CI = 0.44–0.90) and a stronger

association with long-term use (≥5 years MHT use vs never use, HR = 0.55, 95% CI = 0.35–0.87, *P*_{trend} = 0.01) and with current, but not former, use (current MHT use at baseline vs never use, HR = 0.60, 95% CI = 0.39–0.90). We carried out exploratory analyses to compare reproductive factors between serous and non-serous cases and observed significant heterogeneity in the risk associations for MHT use and OC duration of use (*P*_{int} ≤ 0.01) (Supplementary Table 1). In contrast with the improved survival observed among serous cases who reported MHT use, there appeared to be a higher risk of death among non-serous cases who used MHT. Given that only 23 deaths occurred among 45 non-serous cases who reported MHT use, this finding should be interpreted with caution.

In a uniform subgroup of FIGO stage II/III cases (all histological subtypes), there was no association between OC use or OC duration of use with EOC-specific survival (Supplementary Table 2). Compared with never users of MHT, we observed a non-significant improved survival with ever use of MHT in stage II/III cases (HR = 0.67, 95% CI = 0.41–1.08), but there was no trend with duration of MHT use (*P*_{trend} = 0.45). Although based on only 29 stage II/III cases with an early menopause, we observed a worse survival in women who reported an early age at menopause (menopause age ≤45 years vs ≥45–≤50, HR = 2.05, 95% CI = 1.04–4.01); this result contrasted with the null association with menopausal age that was observed in the analyses of EOC overall and serous cases. We carried out further stratified analyses to compare risk associations between cases diagnosed with early stage (FIGO SI/II) vs late stage (FIGO SIII) tumours and observed no significant heterogeneity (*P*_{int} ≥ 0.06) (data not shown). In the sensitivity analyses restricted to postmenopausal cases at recruitment (*n* = 646) whose reproductive exposures were unlikely to change, we observed similar results to analyses of EOC overall (Supplementary Table 3). Finally, compared with never users of MHT (crude analyses), MHT users tended to be younger, had a slightly lower BMI, were more likely to ever use OCs and used OCs for a longer duration and a higher proportion were diagnosed with serous tumours (Supplementary Table 4). There were no differences for other factors, including tumour grade or stage in relation to MHT use.

Table 3. Association between prediagnostic reproductive factors and survival among serous EOC cases

	Total ^a n	Fatal cases ^b n (%)	Model 1 HR ^c	95% CI	Model 2 HR ^d	95% CI
Age at menarche^e, years						
< 12	84	48 (57.1)	Ref.		Ref.	
12	102	50 (49.0)	0.98	0.64–1.51	1.10	0.71–1.69
13	145	76 (52.4)	0.92	0.62–1.38	0.82	0.55–1.23
14	134	67 (50.0)	0.86	0.58–1.30	0.79	0.52–1.20
> 14	98	54 (55.1)	1.02	0.66–1.57	0.92	0.59–1.44
<i>P</i> _{trend}				0.80		0.69
Parous^e						
No	86	49 (57.0)	Ref.		Ref.	
Yes	474	245 (51.7)	0.94	0.68–1.30	0.96	0.69–1.33
Number of FTPs^{e,f}						
1	101	48 (47.5)	Ref.		Ref.	
2	215	109 (50.7)	1.22	0.85–1.76	0.95	0.64–1.39
3+	148	82 (55.4)	1.47	1.00–2.16	1.10	0.73–1.65
<i>P</i> _{trend}				0.05		0.38
Age at first FTP^{e,f}, years						
≤ 20	61	31 (50.8)	Ref.		Ref.	
> 20–≤ 25	208	94 (45.2)	0.68	0.44–1.04	0.59	0.38–0.92
> 25–≤ 30	145	83 (57.2)	0.82	0.53–1.28	0.75	0.47–1.20
> 30	56	35 (62.5)	0.76	0.45–1.28	0.71	0.40–1.23
<i>P</i> _{trend}				0.65		0.75
Breastfeeding^{f,g}						
Never	69	34 (49.3)	Ref.		Ref.	
Ever	376	192 (51.1)	0.88	0.59–1.31	0.92	0.61–1.38
Duration of breastfeeding^h, years						
≤ 3	130	65 (50.0)	Ref.		Ref.	
> 3–≤ 6	75	39 (52.0)	1.05	0.68–1.61	1.07	0.68–1.69
> 6–≤ 12	75	33 (44.0)	0.61	0.38–0.98	0.60	0.37–0.99
> 12–≤ 24	69	38 (55.1)	0.93	0.59–1.45	0.90	0.56–1.43
> 24	27	17 (63.0)	1.12	0.62–2.02	1.13	0.61–2.08
<i>P</i> _{trend}				0.59		0.48
OC use^e						
Never	275	148 (53.8)	Ref.		Ref.	
Ever	289	147 (50.9)	1.01	0.78–1.31	0.95	0.73–1.23
Duration of OC use^{i,j}, years						
≤ 1	67	30 (44.8)	Ref.		Ref.	
> 1–≤ 5	94	50 (53.2)	0.96	0.58–1.60	1.05	0.61–1.78
> 5–≤ 10	58	26 (44.8)	0.92	0.52–1.64	1.15	0.63–2.12
> 10	46	28 (60.9)	1.42	0.80–2.51	1.31	0.71–2.40
<i>P</i> _{trend}				0.31		0.42
Age at menopause^{k,l}						
≤ 45	52	33 (63.5)	1.26	0.79–2.02	1.38	0.83–2.30
> 45–≤ 50	112	65 (58.0)	Ref.		Ref.	
> 50–≤ 52	55	29 (52.7)	0.98	0.61–1.58	0.97	0.58–1.61
> 52	68	45 (66.2)	1.16	0.77–1.77	1.11	0.71–1.75
<i>P</i> _{trend}				0.88		0.64
MHT use^{e,k,m}						
Never	151	94 (62.3)	Ref.		Ref.	
Ever	144	80 (55.6)	0.71	0.50–1.00	0.63	0.44–0.90
MHT timing of use at baseline^{e,k,m}						
Former	42	25 (59.5)	0.86	0.54–1.38	0.73	0.45–1.18
Current	101	54 (53.5)	0.65	0.44–0.96	0.60	0.39–0.90
MHT duration of use at baseline^{k,m,n}, years						
< 5	78	43 (55.1)	0.81	0.54–1.22	0.79	0.51–1.21
≥ 5	52	29 (55.8)	0.64	0.41–1.00	0.55	0.35–0.87
<i>P</i> _{trend}				0.07		0.01
MHT formulation at baseline (current users only)^{k,m,o}						
E only	21	16 (76.2)	0.74	0.41–1.32	0.64	0.34–1.18
E + P	65	32 (49.2)	0.63	0.39–1.01	0.61	0.36–1.02
Other	7	3 (42.9)	0.35	0.08–1.53	0.35	0.08–1.50
Hysterectomy^p						
No	452	231 (51.1)	Ref.		Ref.	
Yes	58	31 (53.4)	0.82	0.55–1.23	0.80	0.53–1.21

Table 3. (Continued)

	Total ^a n	Fatal cases ^b n (%)	Model 1 HR ^c	95% CI	Model 2 HR ^d	95% CI
Total ovulatory years^g						
≤27.5	119	57 (47.9)	Ref.		Ref.	
>27.5–≤33.0	117	65 (55.6)	1.34	0.90–1.98	1.33	0.87–2.04
>33.0–≤36.5	124	55 (47.4)	0.75	0.49–1.13	0.73	0.47–1.13
>36.5	101	61 (60.4)	1.22	0.80–1.84	1.22	0.79–1.88
<i>P</i> _{trend}				0.74		0.72

Abbreviations: CI = confidence interval; EOC = epithelial ovarian cancer; FTP = full term pregnancy; HR = hazard ratio, MHT = menopausal hormone therapy; OC = oral contraceptive.

^aTotal number of serous cases *n* = 568.

^bTotal number of fatal serous cases *n* = 298.

^cAdjusted for age at diagnosis (continuous) and stratified by study centre.

^dAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI (<23 kg m⁻², ≥23–<25 (reference), ≥25–<30, ≥30), tumour stage (local (reference), regional, metastatic and unknown), smoking status (never (reference), former, current and unknown) and stratified by study centre.

^eMissing for ≤2.1% of the cohort.

^fAmong parous women only.

^gBreastfeeding was missing for 6.1% of the cohort.

^hAmong parous women who had ever breastfed.

ⁱAmong OC users only.

^jDuration of OC use was missing for 8.3% of women.

^kAmong postmenopausal women only.

^lAge at menopause was missing for 18.5% of postmenopausal women.

^mParticipants from Greece and Sweden were excluded from this analysis as detailed data on MHT use were unavailable.

ⁿMHT duration was missing for 9.7% of individuals who ever used MHT.

^oMHT formulation was missing for 7.9% of individuals who reported current use.

^pHysterectomy was missing for 10.2% of the cohort.

^qTotal ovulatory years was missing for 18.8% of the cohort.

DISCUSSION

To our knowledge, the current study was the largest to date to investigate reproductive factors and EOC-specific survival. In the analyses of EOC overall, compared with never users of MHT, long-term MHT users had a better survival and there also was a non-significant improved survival in ever users of MHT. In contrast, previous studies of ever *vs* never use of MHT reported no influence on survival (Mascarenhas *et al*, 2006; Nagle *et al*, 2008; Wernli *et al*, 2008; Zhang and Holman, 2012). Similar to earlier studies (Mascarenhas *et al*, 2006; Wernli *et al*, 2008), we observed no difference in survival according to MHT formulation. Among serous cases, in comparison with never users of MHT, we observed a better survival among women who had ever used MHT and specifically among long-term and current MHT users at the study baseline. The observation of an improved survival among serous cases for ever *vs* never MHT use is consistent with an earlier Swedish study (Mascarenhas *et al*, 2006), while the only other study that investigated serous EOC (Nagle *et al*, 2008) reported no association. These results highlight the possibility that MHT use may have a divergent influence on EOC, wherein MHT users may have a better survival, which contrasts with the increased risk of developing incident serous (and endometrioid) EOC based on a recent meta-analysis of 52 epidemiological studies (Beral *et al*, 2015). Further studies are needed to investigate MHT use in relation to survival among serous cases and to extend this analysis to other individual histological subtypes of EOC as we were unable to address this issue in the current study owing to the limited sample size.

Consistent with earlier studies (Kjaerbye-Thygesen *et al*, 2006; Nagle *et al*, 2008; Yang *et al*, 2008; Robbins *et al*, 2009; Zhang and Holman, 2012), we observed that ever use of OCs was not associated with EOC survival; however, in the current study a longer duration of OC use among ever users of OCs was unexpectedly associated with a worse survival. This result contrasted with two prior reports that observed no influence of OC duration on EOC survival (Kjaerbye-Thygesen *et al*, 2006;

Yang *et al*, 2008). In the current study, there was no association between OC duration and survival in the analyses restricted to serous cases. As this was the only report where a longer duration of OC use was associated with worse survival in EOC overall, this may be a chance finding.

We noted that the following reproductive factors, namely, parity, breastfeeding, age at menarche and menopause, hysterectomy and total ovulatory years were not associated with EOC-specific survival in the analyses of EOC overall or serous cases. These null associations were consistent with the earlier Australian study and systematic review of seven studies (Nagle *et al*, 2008) and subsequent reports (Yang *et al*, 2008; Zhang and Holman, 2012; Robbins *et al*, 2009), with the following exceptions: reproductive factors that were associated with a worse survival included an older age at first delivery (Jacobsen *et al*, 1993), younger age at menarche and increasing ovulatory years (Kjaerbye-Thygesen *et al*, 2006; Robbins *et al*, 2009), while breastfeeding was associated with a better survival (Nagle *et al*, 2008).

Key strengths of this study include the large number of cases and the representation of findings from 10 European countries. Potential limitations of this study were that the exposure data were collected on average 6 years prior to diagnosis; however, the impact of this was likely limited for reproductive exposures that occurred during childbearing years; the majority (63%) of the cases in the study were postmenopausal at recruitment and had completed their reproductive history. Furthermore, in sensitivity analyses that were restricted to postmenopausal women, we observed similar results to the overall analysis. For MHT, it would have been informative if follow-up questionnaire data were available to compare use before and after diagnosis; however, we only had information on MHT use at recruitment in the current study. Thus it is possible that some of the current MHT users may have ceased their use after recruitment, or non-MHT users at baseline might have subsequently commenced MHT use; these factors would be expected to attenuate the risk estimates towards the null. We used a summary staging variable (local, regional, metastatic and unknown) to adjust for the extent of disease, but data were unavailable for other prognostic factors such as the amount of

residual disease remaining after surgery and information on treatment. To account for possible variation in the treatment offered between the EPIC study centres, we stratified by the study centre in all the statistical models. As treatment is likely to be uniform following tumour staging guidelines (Prat, 2014), we adjusted for stage to account for potential differences in the treatment received. Finally, as a large number of statistical tests were performed in this analysis, the significant results may be chance findings.

In conclusion, in this report from the EPIC study we observed that most reproductive factors did not appear to influence survival from EOC. Together with results from the earlier Swedish study (Mascarenhas *et al*, 2006), our findings strengthen the evidence for a possible improvement in survival for serous EOC cases who had ever used MHT. It will be important to investigate this result further particularly in relation to the timing of MHT use and to examine whether MHT use may be associated with survival in individual non-serous histologic subtypes of EOC.

ACKNOWLEDGEMENTS

The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); ERC-2009-AdG 232997 and Nordic Center of Excellence programme on Food, Nutrition and Health. (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Silva Azevedo E, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP (2014) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* **385**(9972): 977-1010.
- Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet* **371**(9609): 303-314.
- Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet* **385**(9980): 1835-1842.
- Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. *J Natl Cancer Inst* **71**(4): 717-721.
- Cunat S, Hoffmann P, Pujol P (2004) Estrogens and epithelial ovarian cancer. *Gynecol Oncol* **94**(1): 25-32.
- Fortner RT, Ose J, Merritt MA, Schock H, Tjonneland A, Hansen L, Overvad K, Dossus L, Clavel-Chapelon F, Baglietto L, Boeing H, Trichopoulou A, Benetou V, Lagiou P, Agnoli C, Mattiello A, Masala G, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Weiderpass E, Torhild GI, Duell EJ, Larranaga N, Ardanaz E, Sanchez MJ, Chirlaque MD, Brandstedt J, Idahl A, Lundin E, Khaw KT, Wareham N, Travis RC, Rinaldi S, Romieu I, Gunter MJ, Riboli E, Kaaks R (2015) Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort. *Int J Cancer* **137**: 1196-1208.
- Grambsch P, Therneau T (1994) Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika* **81**: 515-526.
- Greenland S (1989) Modeling and variable selection in epidemiologic analysis. *Am J Public Health* **79**(3): 340-349.
- Jacobsen BK, Vollset SE, Kvale G (1993) Reproductive factors and survival from ovarian cancer. *Int J Cancer* **54**(6): 904-906.
- Jarboe EA, Folkens AK, Drapkin R, Ince TA, Agoston ES, Crum CP (2008) Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. *Histopathology* **53**(2): 127-138.
- Kjaerbye-Thygesen A, Frederiksen K, Hogdall EV, Hogdall CK, Blaakaer J, Kjaer SK (2006) Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables. *Eur J Gynaecol Oncol* **27**(5): 467-472.
- Kurman RJ, Shih I (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. *Hum Pathol* **42**(7): 918-931.
- Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quiros JR, Martinez C, Tormo MJ, Wirfalt E, Berglund G, Hallmans G, Key TJ, Reeves G, Bingham S, Norat T, Biessy C, Kaaks R, Riboli E (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* **111**(5): 762-771.
- Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. *Int J Cancer* **119**(12): 2907-2915.
- Modesitt SC, van Nagell Jr JR (2005) The impact of obesity on the incidence and treatment of gynecologic cancers: a review. *Obstet Gynecol Surv* **60**(10): 683-692.
- Modugno F, Laskey RA, Smith AL, Andersen CL, Haluska P, Oesterreich S (2012) Hormone response in ovarian cancer: time to reconsider as a clinical target? *Endocr Relat Cancer* **19**(6): R255-R279.
- Nagle CM, Bain CJ, Green AC, Webb PM (2008) The influence of reproductive and hormonal factors on ovarian cancer survival. *Int J Gynecol Cancer* **18**(3): 407-413.
- Prat J (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet* **124**(1): 1-5.
- R Core Team (2014) *R: A language and environment for statistical computing*. R Foundation for Statistical Computing: Vienna, Austria. Available at <http://www.R-project.org/> (accessed 12 September 2014).
- Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou A, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters PH, Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, Kaaks R, Saracci R (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* **5**(6B): 1113-1124.
- Riman T, Nilsson S, Persson IR (2004) Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. *Acta Obstet Gynecol Scand* **83**(9): 783-795.

- Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. *J Natl Cancer Inst* **90**(23): 1774–1786.
- Robbins CL, Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Kulkarni A, Marchbanks PA (2009) Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis. *Cancer Epidemiol Biomarkers Prev* **18**(7): 2035–2041.
- Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J (2009) Ovarian cancer: pathology, biology, and disease models. *Front Biosci (Landmark Ed)* **14**: 2089–2102.
- Tew WP, Muss HB, Kimmick GG, von Gruenigen VE, Lichtman SM (2014) Breast and ovarian cancer in the older woman. *J Clin Oncol* **32**(24): 2553–2561.
- Therneau T (2014) A Package for Survival Analysis in S. R package version 2.37-7.
- Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L, Tjonneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R, Schutze M, Steffen A, Bamia C, Trichopoulos A, Zylis D, Masala G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duynhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Travier N, Sanchez MJ, Huerta JM, Ardanaz E, Larranaga N, Jirstrom K, Manjer J, Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer* **105**(9): 1436–1442.
- Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM (2008) Hormone therapy and ovarian cancer: incidence and survival. *Cancer Causes Control* **19**(6): 605–613.
- Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. *Am J Epidemiol* **136**(10): 1184–1203.
- Yang L, Klint A, Lambe M, Bellocchio R, Riman T, Bergfeldt K, Persson I, Weiderpass E (2008) Predictors of ovarian cancer survival: a population-based prospective study in Sweden. *Int J Cancer* **123**(3): 672–679.
- Zhang M, Holman CD (2012) Tubal ligation and survival of ovarian cancer patients. *J Obstet Gynaecol Res* **38**(1): 40–47.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

¹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK; ²Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany; ³Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, University Campus, Ioannina 45110, Greece; ⁴Department of Community Medicine, Faculty of Health Sciences, University of Tromsø–The Arctic University of Norway, Tromsø N–9037, Norway; ⁵Department of Research, Cancer Registry of Norway, PB 5313 Majorstuen, 0304 Oslo, Norway; ⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, Stockholm 17177, Sweden; ⁷Genetic Epidemiology Group, Folkhälsan Research Center, FI-00290 Helsinki, Finland; ⁸Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Huispost Str. 6.131, PO Box 85500, Utrecht 3508 GA, The Netherlands; ⁹Inserm, Center for Research in Epidemiology and Population Health (CESP), U1018, Lifestyle, Genes and Health: Integrative Trans-generational Epidemiology, Villejuif F-94805, France; ¹⁰Université Paris Sud, UMRS 1018, Villejuif F-94805, France; ¹¹Institut Gustave Roussy, Villejuif F-94805, France; ¹²Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen DK-2100, Denmark; ¹³Section for Epidemiology, Department of Public Health, Aarhus University, Bartholins Alle 2, Aarhus C DK-8000, Denmark; ¹⁴Cancer Epidemiology Center, Cancer Council of Victoria, 615 St Kilda Road, Melbourne 3004, Victoria, Australia; ¹⁵Center for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne 3010, Victoria, Australia; ¹⁶Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Arthur-Scheunert-Allee 114–116, Nuthetal 14558, Germany; ¹⁷Hellenic Health Foundation, 13 Kaisareias Street, Athens GR-115 27, Greece; ¹⁸Bureau of Epidemiologic Research, Academy of Athens, 23 Alexandroupoleos Street, Athens GR-115 27, Greece; ¹⁹Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA; ²⁰Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Mikras Asias 75, Goudi, Athens GR-115 27, Greece; ²¹Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute–ISPO, Ponte Nuovo Palazzina 28A ‘Mario Fiori’, Via delle Oblate 4, Florence 50141, Italy; ²²Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1, Milano 20133, Italy; ²³Cancer Registry and Histopathology Unit, ‘Civic–M.P. Arezzo’ Hospital, ASP, Via Dante No. 109, Ragusa 97100, Italy; ²⁴Unit of Epidemiology, Regional Health Service ASL TO3, Via Sabaudia 164, Grugliasco (TO) 10095, Italy; ²⁵Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Via Santena 7, Turin 10126, Italy; ²⁶Dipartimento di Medicina Clinica e Chirurgia, Federico II University, via Pansini 5, 80131 Naples, Italy; ²⁷Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, Bilthoven 3720 BA, The Netherlands; ²⁸Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 cx, The Netherlands; ²⁹Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; ³⁰Public Health Directorate, Asturias, Ciriaco Miguel Vigil St 9, Oviedo 33006, Spain; ³¹Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Avda Gran Via 199-203, 08908 L’Hospitalet de Llobregat, Barcelona, Spain; ³²Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs, Hospitales Universitarios de Granada/Universidad de Granada, Cuesta del Observatorio, 4, Campus Universitario de Cartuja, Granada 18080, Spain; ³³CIBER de Epidemiología y Salud Pública (CIBERESP), Melchor Fernández Almagro, 3-5, Madrid 28029, Spain; ³⁴Public Health Division of Gipuzkoa, Regional Government of the Basque Country, Donostia, Spain; ³⁵Department of Epidemiology, Murcia Regional Health Council, IMIB–Arrixaca, Ronda de Levante 11, Murcia 30008, Spain; ³⁶Navarra Public Health Institute, c/Leyre 15, Pamplona 31003, Spain; ³⁷IdiSNA, Navarra Institute for Health Research, Recinto de Complejo Hospitalario de Navarra c/ Irunlarrea 3, Pamplona 31008, Spain; ³⁸Department of Clinical Sciences Malmö, Lund University, Malmö 20502, Sweden;

³⁹Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, SE-901 87 Umeå, Sweden; ⁴⁰Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, SE-901 87 Umeå, Sweden; ⁴¹Department of Medical Biosciences and Pathology, Umeå University, Umeå SE-901 87, Sweden; ⁴²MRC Epidemiology Unit, University of Cambridge, Institute of Metabolic Science, Box 285, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK; ⁴³School of Clinical Medicine, University of Cambridge, Addenbrooke's Hospital, Hills Rd, Cambridge CB2 0SP, UK; ⁴⁴Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Oxford OX3 7LF, UK and ⁴⁵International Agency for Research on Cancer, 150 Cours Albert-Thomas, Lyon Cedex 08 69372, France

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)